B Cell Protein Factory: How HSPC Gene Editing Could Turn B Cells into Long-Term Therapeutic Protein Factories

Executive Summary

• B cell protein factory represents a new paradigm for biologics delivery

• Through HSPC gene editing, B cells can be engineered to continuously secrete antibodies or therapeutic proteins

• The system is boostable, long-term, and capable of multi-protein output

• This signals a shift in cell therapy—from “killing cells” to “producing proteins”

• Companies like Be Biopharma and Immusoft are already moving in this direction

Introduction: Are We Redefining Biologics?

B cell protein factory is emerging as one of the most intriguing directions in next-generation biotech platforms.

In the traditional biologics world, the workflow is familiar:

• Design a protein or antibody

• Manufacture it

• Inject it

• Maintain its concentration in circulation

This model is mature—but fundamentally, it is still:

👉 Exogenous drug delivery

Now, a new question is beginning to take shape:

👉 What if the body could continuously produce its own therapeutics?

Recent research suggests that through HSPC gene editing, we may be able to transform B cells into:

• Long-lived

• Immune-amplifiable

• Continuous protein-secreting systems

👉 A true in vivo protein factory

What Is a B Cell Protein Factory?

A B cell protein factory refers to:

👉 Leveraging the natural secretory capacity of B cells—especially plasma cells👉 And converting them into long-term therapeutic protein production systems

Core Advantages

• High secretion capacity (plasma cells)

• Long-term survival (bone marrow niche)

• Antigen-driven expansion (boostability)

The Real Shift

This is not just about expressing a protein.

👉 It’s about turning the immune system into a programmable production platform

What Does This Study Actually Do?

The key innovation of this paper is:

👉 Editing hematopoietic stem and progenitor cells (HSPCs), instead of directly modifying B cells

Workflow

1. Edit HSPCs using CRISPR/Cas9

2. Insert antibody or protein genes into the IgH locus

3. Transplant back into the host

4. Differentiate into B cells

5. Antigen stimulation → expansion

6. Differentiate into plasma cells

7. Sustain long-term protein secretion

Key Functional Features

• Entry into germinal centers

• Formation of memory B cells

• Differentiation into plasma cells

• Antigen-driven boosting

👉 This means:

Protein expression is no longer static—it becomes part of a dynamic immune response

Why This Platform Matters

1. B Cells as Biologics Factories

Traditionally:

👉 B cells = source of antibodies

Now:

👉 B cells = protein production platform

Potential Outputs

• Antibodies

• Enzyme replacement proteins

• Cytokines

• Decoy receptors

• Immune modulators

2. Boostability: Therapy That Can Be Amplified

   
   

One of the most important features of this system:

👉 Protein expression can be increased via immunization

Traditional vs. New Model

Traditional Biologics	B Cell Protein Factory
Fixed dosing	Boostable
PK-driven	Immune-driven
Passive maintenance	Active expansion

👉 This represents a fundamental shift:

Therapy begins to borrow logic from vaccines

3. Small Numbers Can Scale

The study shows:

👉 Even a small number of edited HSPCs👉 Can expand and generate meaningful output in vivo

Why This Matters

The system relies on:

👉 Clonal expansion—not initial dose

This has major implications for:

👉 In vivo gene editing

Even low editing efficiency may be sufficient—if the system can amplify.

Not Just HIV: This Is a Platform

This study demonstrates multiple applications:

HIV

• Long-term antibody expression

• Boostable response

Malaria

• Functional antibody production

• Parasite inhibition

Influenza

• Protective immunity

• Survival against lethal challenge

👉 The takeaway is clear:

This is not a single-use solution—it is a platform

How Is This Different from Traditional Engineered B Cells?

Approach	Characteristics
Traditional engineered B cells	Ex vivo / short-term
HSPC-based system	Long-term / self-renewing
Traditional biologics	Exogenous
Protein factory model	In vivo production

👉 The key difference:

Long-term self-renewal capability

Who Is Building in This Space?

Be Biopharma

• Engineered B cell medicines

• Long-term protein expression

• Focus on hemophilia

👉 Closest to the platform-level vision

Immusoft

• Immune System Programming (ISP)

• “Living biofactories”

• Already in clinical trials

👉 Demonstrates real-world feasibility

What Is Truly Disruptive About This?

This is not just a new technique—it’s a system-level shift.

🔁 Drug → System

From administering a drug → building a production system

📈 Dose → Expansion

From dose control → immune amplification

🔬 PK → Biology

From pharmacokinetics → immune dynamics

Real-World Challenges

This approach still faces major hurdles:

• Complexity of HSPC transplantation

• Safety and off-target risks

• Manufacturing and CMC challenges

• Cost and scalability

👉 This is still an early-stage field

My Perspective: Cell Therapy Is Changing Roles

In the past decade:

👉 CAR-T = killing cells

In the next decade:

👉 Cells = protein factories

This shift could impact:

• Rare diseases

• Chronic biologics

• Immune modulation

• Long-term therapies

Conclusion

B cell protein factory is more than an extension of engineered B cells.

It represents a deeper shift:

👉 The immune system is being redesigned as a programmable production platform

If this direction succeeds:

👉 Biologics may no longer require repeated dosing

👉 Instead, they may be continuously produced within the body

References

Hartweger H et al. B Lymphocyte Protein Factories produced by Hematopoietic Stem Cell Gene Editing. bioRxiv. 2026

Nahmad AD et al. Engineered B cells for antibody delivery. Nat Biotechnol. 2022

Yin Y et al. Affinity maturation of engineered B cells. Nat Biomed Eng. 2024

Feist WN et al. HSPC-based HIV resistance. Nat Commun. 2025

If you’re interested in:

• Engineered B cells

• Gene editing

• Next-generation biologics

• Cell therapy platforms

Feel free to share this article or join the discussion on my platforms.